Janney Montgomery Scott LLC Has $11.62 Million Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Janney Montgomery Scott LLC boosted its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 15.3% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 349,730 shares of the company’s stock after buying an additional 46,398 shares during the period. Janney Montgomery Scott LLC’s holdings in Teva Pharmaceutical Industries Limited were worth $11,618,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Renaissance Technologies LLC raised its position in Teva Pharmaceutical Industries Limited by 122.4% in the first quarter. Renaissance Technologies LLC now owns 4,817,763 shares of the company’s stock worth $154,602,000 after buying an additional 2,651,900 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. raised its position in Teva Pharmaceutical Industries Limited by 405,409.9% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,435,505 shares of the company’s stock worth $46,065,000 after buying an additional 1,435,151 shares during the last quarter. UBS Asset Management Americas Inc. raised its position in Teva Pharmaceutical Industries Limited by 150.7% in the fourth quarter. UBS Asset Management Americas Inc. now owns 2,004,760 shares of the company’s stock worth $72,672,000 after buying an additional 1,205,253 shares during the last quarter. Ameriprise Financial Inc. raised its position in Teva Pharmaceutical Industries Limited by 142.2% in the first quarter. Ameriprise Financial Inc. now owns 1,288,571 shares of the company’s stock worth $41,349,000 after buying an additional 756,441 shares during the last quarter. Finally, Commerzbank Aktiengesellschaft FI raised its position in Teva Pharmaceutical Industries Limited by 370.6% in the first quarter. Commerzbank Aktiengesellschaft FI now owns 929,084 shares of the company’s stock worth $29,814,000 after buying an additional 731,666 shares during the last quarter. 56.04% of the stock is owned by institutional investors.

Shares of Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 17.30 on Friday. The firm has a 50-day moving average price of $27.46 and a 200-day moving average price of $30.98. Teva Pharmaceutical Industries Limited has a 12 month low of $16.81 and a 12 month high of $53.96. The stock’s market cap is $17.58 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by $0.07. The business had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The business’s revenue was up 12.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.25 EPS. Equities analysts expect that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 14th. Investors of record on Tuesday, August 29th will be issued a dividend of $0.085 per share. The ex-dividend date is Friday, August 25th. This represents a $0.34 annualized dividend and a dividend yield of 1.97%. Teva Pharmaceutical Industries Limited’s payout ratio is -18.95%.

ILLEGAL ACTIVITY WARNING: This story was first reported by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.com-unik.info/2017/08/19/janney-montgomery-scott-llc-raises-stake-in-teva-pharmaceutical-industries-limited-nyseteva-updated-updated.html.

Several brokerages recently weighed in on TEVA. Vetr lowered Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating and set a $31.05 price target for the company. in a research note on Thursday, June 22nd. Cantor Fitzgerald set a $31.00 price target on Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a research note on Thursday, June 22nd. Citigroup Inc. lowered Teva Pharmaceutical Industries Limited from a “buy” rating to a “neutral” rating and cut their price target for the company from $32.00 to $19.00 in a research note on Wednesday. BidaskClub lowered Teva Pharmaceutical Industries Limited from a “sell” rating to a “strong sell” rating in a research note on Wednesday. Finally, Maxim Group restated a “hold” rating and issued a $35.00 price target on shares of Teva Pharmaceutical Industries Limited in a research note on Thursday, July 13th. Three investment analysts have rated the stock with a sell rating, twenty have issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $36.73.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

What are top analysts saying about Teva Pharmaceutical Industries Limited? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Teva Pharmaceutical Industries Limited and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit